Sodium-Glucose Cotransporter 2 Inhibitors

Key Points

• SGLT2 inhibitors reduce renal sodium-glucose reabsorption in the proximal tubule, causing osmotic diuresis.
• Dapagliflozin and empagliflozin are commonly used SGLT2 inhibitors for heart-failure pathways.
• This class reduces heart-failure mortality and is used whether or not type 2 diabetes is also present.
• Major safety risks include volume depletion/hypotension, ketoacidosis (especially in diabetes), and urinary/genital infections.
• Serious rare infection risk includes necrotizing perineal soft-tissue infection.
• Baseline and ongoing renal-status assessment is required before and during therapy.

Pathophysiology

In the proximal tubule, sodium and glucose are cotransported back into circulation. SGLT2 inhibitors block this pathway, so more sodium and glucose remain in the tubular lumen and are excreted in urine.

Because sodium and glucose are osmotically active, water excretion also increases. This mild diuretic effect can reduce preload in heart failure and decrease hemodynamic stress on the ventricle.

Classification

• Dapagliflozin (Farxiga): 10 mg orally once daily (max 10 mg/day).
• Empagliflozin (Jardiance): 10 mg orally once daily (max 10 mg/day).

Nursing Assessment

NCLEX Focus

Prioritize volume status and renal function before first dose; untreated dehydration can precipitate significant hypotension.

• Assess baseline blood pressure, pulse, and hydration status before initiation.
• Screen for dehydration signs before dosing (for example dry mouth, lightheadedness, skin tenting, tachycardia, sunken eyes).
• Assess renal status before starting and throughout therapy.
• Assess diabetes context and concurrent insulin use because hypoglycemia risk can increase with combination therapy.
• Screen for infection symptoms (urinary, renal, genital/perineal) and escalate concerning findings promptly.

Nursing Interventions

• Monitor blood pressure and pulse during initiation and dose adjustments.
• Track renal function and report worsening renal trends promptly.
• Reinforce hydration and teach early reporting of dizziness/lightheadedness or other volume-depletion cues.
• In patients on insulin, coordinate glucose-monitoring intensity and dose-adjustment communication.
• Teach urgent reporting for UTI/pyelonephritis cues, genital infection symptoms, or severe perineal pain/swelling/fever.
• Reconcile concurrent medications and supplements for interaction risk, including lithium and glucose-lowering therapies.

Volume and Infection Safety

SGLT2 inhibitors can cause clinically significant dehydration/hypotension and have rare severe perineal infection risk; early cue recognition and escalation are critical.

Pharmacology

Drug/Class	Typical Dose	Key RN Considerations
Dapagliflozin	10 mg PO daily (max 10 mg/day)	Assess volume and renal status before/during therapy; monitor for hypotension, ketoacidosis, and infection
Empagliflozin	10 mg PO daily (max 10 mg/day)	Same class monitoring priorities; reinforce hydration and glucose safety with insulin co-use

Clinical Judgment Application

Clinical Scenario

A patient with HFrEF and type 2 diabetes starts dapagliflozin and returns with new dizziness and poor oral intake.

• Recognize Cues: Dizziness, reduced intake, and new SGLT2I exposure suggest volume depletion risk.
• Analyze Cues: Osmotic diuresis may be worsening intravascular depletion and hypotension.
• Prioritize Hypotheses: Immediate risk is hemodynamic instability and renal hypoperfusion.
• Generate Solutions: Reassess vitals/hydration, review renal labs and glucose, and evaluate infection symptoms.
• Take Action: Hold/escalate per protocol, notify provider, and implement hydration and safety plan.
• Evaluate Outcomes: Blood pressure, renal trends, and symptoms stabilize with adjusted therapy.

Related Concepts

• heart-failure - SGLT2 inhibitors are a guideline-directed class in HFrEF management.
• diabetes-mellitus - Class was first adopted in type 2 diabetes and requires glucose-safety planning.
• diuretics - Osmotic/volume effects overlap with broader diuretic monitoring priorities.
• acute-kidney-injury - Renal surveillance is required during initiation and continuation.
• potassium-balance-disorders - Electrolyte and renal trend monitoring remains part of safety surveillance.

Self-Check

1. Why can SGLT2 inhibitors improve heart-failure outcomes even in patients without diabetes?
2. Which pre-dose assessment findings should delay administration and prompt provider contact?
3. What infection and hemodynamic symptoms require urgent escalation during SGLT2I therapy?